Accueil > Les actualités > ErVaccinces Technologies raises €4.5M and announces first cancer vaccine candidate to enter clinic stage
ErVaccinces Technologies raises €4.5M and announces first cancer vaccine candidate to enter clinic s...
Publié le 12/01/2023
The biotec company ErVaccine Technologies, spin-off of the Centre Léon Bérard and the CRCL, which develops next-generation therapeutic vaccines and cellular immunotherapies targeting “unconventional” tumor antigens, such as those derived from HERVs, announces the closing of a €4.5 million financing round with Seventure and Bpifrance within the framework of the Aide au Développement de l’Innovation (ADI) program.
These funds are dedicated to financing ErVaccine’s work with its development portfolio, which currently includes nine projects, two of which are in advanced preclinical development.
After obtaining the publication of three major scientific articles* in 2022, ErVaccine Technologies is announcing the clinical entry of its first vaccine candidate in 2023.
Nathalie Donne, CEO of ErVaccine, said: “The work of ErVaccine’s teams, led by Professor Stéphane Depil, and the support of our strategic investors, Seventure and Bpifrance, has enabled us to make decisive progress in our preclinical programs and to bring us to the doorstep of the first human trials. At the same time, throughout the year, we published numerous non-clinical data of high scientific quality, confirming the immense potential of our technology. These publications have enabled us to make progress in our discussions with several international investors specialized in life sciences, with a view to our next financing stage, as well as with potential industrial partners.